ECG Criteria for Left Ventricular Hypertrophy in Hypertensive Black Africans: Insights from the CoArtHA Trial.

Annina Vischer[1,5*], MD; Valeriya Nemtsova[1*],MD; Blaise Lukau[2], MD; Martin Rohacek, MD[3,4,5,6]; Jonathan Macko, BSc[1]; Johanna Oehri, MD[1,4,5]; Herry Mapesi, PhD[3,4,5]; Fiona Vanobberghen, PhD[4,5]; Andrew Katende, MD[3,6]; Ravi Gupta, MD[7]; Herieth Ismael Wilson, MD[3]; Alain Amstutz, PhD[8,9,10]; Josephine Muhairwe, MD[7,11]; Elizabeth Senkoro, MD[3]; Theonestina Byakuzana,Bsc[3]; Geofrey Mbunda, Dip[3]; Jamali Siru,Dip[3]; Winfrid Gingo, MD[6]; Niklaus Daniel Labhardt, MD[4,5,7,8,12], Maja Weisser, MD[3,4,5,12], Thilo Burkard, MD[1,5,13]

[1] Medical Outpatient Department and Hypertension Centre, ESH Hypertension Centre of Excellence, University Hospital Basel, Basel, Switzerland

[2]SolidarMed, Partnerships for Health, Maseru, Lesotho

[3]Ifakara Health Institute, Ifakara branch, Ifakara, United Republic of Tanzania

[4] Swiss Tropical and Public Health Institute, Allschwil, Switzerland

[5]University of Basel, Basel, Switzerland

[6]St. Francis Regional Referral Hospital, Ifakara, United Republic of Tanzania

[7]SolidarMed, Partnerships for Health, Maseru, Lesotho

[8]Division of Clinical Epidemiology, Department of Clinical Research; University Hospital Basel, Basel, Switzerland

[9] Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway

[10] Bristol Medical School, University of Bristol, Bristol, United Kingdom

[11]Agency for Development, Washington, DC, US

[12] Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland

[13], Department of Cardiology, University Hospital Basel, Basel, Switzerland

***equal contribution**

Short title: ECG criteria for LVH in Hypertensive Africans

Corresponding author:

PD Dr. med. Thilo Burkard, FESC, ISHF

Thilo.Burkard@usb.ch

University Hospital Basel

Medical Outpatient Department and Hypertension Centre

Petersgraben 4

4031 Basel, Switzerland

ORCID: https://orcid.org/0000-0001-6373-9820

Word count: 4616 words (Introduction to Acknowledgments)

Abstract

Background:

Electrocardiographic (ECG) criteria for detecting left ventricular hypertrophy (LVH) were derived largely from non-African populations. Whether these indices accurately identify LVH in African adults with untreated hypertension remains uncertain.

Objective:

To evaluate the diagnostic accuracy of established ECG-LVH criteria compared with echocardiographic left ventricular mass index (LVMI) in Black African adults with untreated, uncomplicated hypertension enrolled in the CoArtHA trial.

Methods:

In this subanalysis, we included participants from rural Tanzania and Lesotho who underwent baseline 12-lead ECG and focused transthoracic echocardiography (fTTE). LVH was defined as LVMI > 95 g/m² in women and > 115 g/m² in men. Diagnostic performance of multiple ECG-LVH criteria was assessed using Spearman correlation, sensitivity, specificity, and area under the receiver-operating characteristic curve (AUC).

Results:

Echocardiographic LVH was present in 56 participants (5%). Among continuous ECG indices, the Cornell voltage product adjusted by + 0.8 mV in women showed the highest correlation with LVMI (rho = 0.373, $p < 0.001$) and achieved the best overall discrimination (AUC = 0.719). Standard cut-offs provided a specificity of 79.5% and sensitivity of 64.3%, whereas an adapted cut-off of 277.8 mV*ms increased specificity above 90%. Other indices, including MESA- and Sokolow-Lyon-based criteria, showed limited accuracy.

Conclusions:

In this large cohort of hypertensive Black African adults, the Cornell voltage product (with + 0.8 mV adjustment for women) demonstrated the best diagnostic performance for detecting LVH compared with echocardiography. These results highlight the need to verify the diagnostic validity of established ECG criteria in African populations and support their pragmatic use to guide cardiovascular risk stratification in low-resource settings.

Keywords: hypertension**,** left ventricular hypertrophy, echocardiography, electrocardiographic criteria, sub-Saharan Africa,

Trial registration: Clinicaltrials.gov NCT04129840. Registered on 17 October 2019 (https://www.clinicaltrials.gov/).

INTRODUCTION

Left ventricular hypertrophy (LVH) is a recognized complication of hypertension and associated with a worse prognosis, independent of ethnicity(1). While cardiac magnetic resonance (CMR) is considered the reference method for assessing LV mass, its availability in low-resource settings is limited. Transthoracic echocardiography (TTE) remains the preferred modality in clinical practice, yet even this is often inaccessible in rural regions of sub-Saharan Africa (2, 3). In contrast, electrocardiography (ECG) is inexpensive and widely available, but its diagnostic accuracy for LVH varies considerably (4-6). Most ECG-LVH criteria were developed in predominantly Caucasian populations, with limited validation among African adults (7, 8). Only few studies have evaluated the suitability of the ECG criteria for LVH assessment in adult black African populations (5, 9). In the MESA (the Multi-Ethnic Study of Atherosclerosis) study, the MESA ECG-LVH index was the best at diagnosing LVH in the subgroup of African Americans when compared to CMR (10).

The CoArtHA trial (Identifying the most effective Treatment Strategies to Control Arterial Hypertension in sub-Saharan Africa) enrolled treatment-naïve adults with uncomplicated hypertension in Tanzania and Lesotho (11, 12). Using this unique dataset, we assessed the diagnostic performance of numerous established ECG-LVH criteria against focused echocardiographic (fTTE) LV mass index (LVMI) and explored optimal cut-off values for this population.

METHODS

Study design and population

The CoArtHA trial was an investigator-initiated, open-label, randomized controlled trial conducted in rural Tanzania and Lesotho to compare three antihypertensive treatment strategies. Detailed methods and eligibility criteria have been published previously (11, 12). In brief, Black African adults (≥18 years) with untreated, uncomplicated hypertension were enrolled. Key exclusion criteria were symptomatic hypertension, recent cardiovascular events, severe comorbidities, pregnancy, or inability to attend follow-up. This subanalysis included all participants with interpretable baseline ECG and fTTE.

All participants gave written informed consent for the collection, storage and use of clinical data and sample specimens for research purposes within the CoArtHA trial. The study protocol of the CoArtHA trial was approved by the Institutional review board of the Ifakara Health Institute, the National Health Research Ethics Committee in Tanzania, the Tanzania Medicines and Medical Devices Authority, the National Health Research and Ethics Committee and Ministry of Health of Lesotho, as well as the Ethics committee of Northwest and Central Switzerland (11, 12).

This was an exploratory analysis of the CoArtHA trial using fTTE and ECG data from baseline investigations. Patients for whom ECG or fTTE data were not available or of insufficient quality, were excluded (Figure 2).

Study procedures

Blood pressure measurement

Blood pressure was measured according to ESC/ESH 2018 guidelines using an automated device (Omron M6 Comfort, HEM-7321-E). Hypertension was defined

as systolic ≥ 140 mmHg and/or diastolic ≥ 90 mmHg. The average of the last two of three measurements was used for analysis.(13, 14).

Electrocardiography

A 12-lead ECG was recorded at baseline using a Schiller AT-1 electrocardiogram machine at 10 mm/mV calibration and at a speed of 25 mm/s.. All ECGs were printed out including an automated matrix analysis of times and amplitudes and were verified by trained investigators under cardiologist supervision. We compared several established ECG-LVH indices with definitions and thresholds summarized in Table 1). Parameters were analyzed as both dichotomous and continuous variables to evaluate correlation and discriminative ability versus echocardiographic LVH as appropriate.

Table 1: *Characteristics of electrocardiographic indexes used in this study*

ECG index	**Definition**	**Cut-off value**
Cornell voltage criteria[10]	SV3 + RaVL	> 2,0 mV for women and > 2,8 mV for men.
Cornell voltage product[13]	(SV3 + RaVL)*QRS	> 244.0mVms[13] Or >243.6 mVms[15]
Cornell voltage product, adjusted for women 0.6 mV	Men: (SV3 + RaVL)*QRS Women: (SV3 + RaVL + 0.6 mV)*QRS	> 244.0mVms[2, 16] Or >243.6 mVms
Cornell voltage product, adjusted	Men: (SV3 + RaVL)*QRS	> 244.0mVms[16]

for women 0.8 mV	Women: (SV3 + RaVL + 0.8 mV)*QRS	Or >243.6 mVms[17]
Novacode 6.1 LVH[18]	RaVL + SV3	≥ 2,600 µV in men ≥ 2,200 µV in women
RaVL[19, 20]		≥ 1.1 mV
general MESA ECG-LVH[21]	SV1 + SV2 + RV5	≥ 4.2 mV
Ethnicity- and gender- MESA ECG-LVH criterion[10]	SV1 + SV2 + RV5	≥ 4.8 in men ≥ 4.3 - in women
Sokolow-Lyon voltage[2]	SV1 + either RV5/RV6, (whichever is higher)	> 3.5 mV
Sokolow-Lyon voltage product [10]	SV_1 + (RV_5/RV_6)*QRS duration	≥ 371000 µVms (371 mVms)
Framingham-adjusted Cornell voltage[10, 22]	Men: [RaVL + SV_3 + 0.0174*(age – 49) + 0.191*(BMI – 26.5)]; Women: [RaVL + SV_3 + 0.0387*(age – 50) + 0.212*(BMI – 24.9)]	Men ≥ 2.8 mV Women ≥ 2.0 mV
Minnesota Code 3.1[23] (LVH without ST-T)	RV5/V6 or RI/II/III/aVF or RaVL	> 2.6 mV > 2 mV > 1.2 mV
Minnesota Code 3.3[23]	RI or	15 mm< or < 20 mm,

	R V5/V6 plus SV1; no MC 3.1	> 35mm
Strain pattern(24, 25)	Coexistence in any of the leads I, II, avL, or V3 to V6: ST-segment horizontal or downward sloping depression >= 0.05 mV, plus negative T-wave; downsloping convex ST-segment with an inverted asymmetrical T-wave opposite to the QRS axis	Yes/No

RaVL – R wave in aVL, BMI- body mass index, MC- Minnesota Code, ECG - electrocardiography, LVH – left ventricular hypertrophy, MESA- the Multi-Ethnic Study of Atherosclerosis

Focused transthoracic echocardiography

Focused echocardiography (fTTE) was performed at baseline by trained study personnel using standardized acquisition protocols and centrally reviewed under the supervision of board certified cardiologists supported by an automated FDA-approved deep-learning workflow (Us2.ai, Singapore) (26, 27). LVM, LVM indexed by BSA and relative wall thickness (RWT) were calculated according to guideline recommendations (LVM defined as 0.8x 1.04x [(IVS + LVID + PWT)^3-LVID^3] + 0.6 grams, where IVS is interventricular septum diastole (unit mm), LVID is left ventricular end-diastolic diameter (units mm), and PWT is posterior wall diastole (units mm)(28). LVH was defined as LVMI >95g/m^2 in women, >115g/m^2 in men (2).

Statistics

For testing the normality of distribution, a Shapiro-Wilk test was used. Normal distribution was defined as a p-value ≥0.05. Continuous data were reported as median (interquartile range), categorical data as n (% of total). Differences between groups were calculated using a Wilcoxon signed rank test for continuous data and using a chi-square test for categorical data.

Testing of ECG parameters

Correlations were calculated with the spearman method using the ggpubr-package (29). Correlations were ranked from (0.01-0.19) indicating no or negligible relationship, to (≥ 0.70) indicating a very strong relationship (Table S1)(30). For accuracy analyses, specificity as (true negative) / (true negative + false positive), sensitivity as (true positive) / (true positive + false negative) was calculated. The negative predictive value (NPV) was calculated as (true negative) / (true negative + false negative). The positive predictive value (PPV) was calculated as (true positive) / (true positive + false positive). The accuracy was calculated as (true positive + true negative) / N. Receiver operating characteristics (ROC) curves were plotted and area under the curves (AUCs) were calculated using the pROC package(31),(32). Discriminative property was graded: AUC of 0.5 suggested no discrimination, 0.7 to 0.8 was considered acceptable, 0.8 to 0.9 was considered excellent, and more than 0.9 was considered outstanding(32). All calculations were completed by using R (33).

Selection of the best ECG-parameters to improve cut-off values

The four best parameters were then selected according to their AUC for further evaluation regarding improved cut-off values for this cohort. Furthermore, the

general MESA ECG-LVH index, as the best ECG-LVH parameter for African Americans in the Mesa Study was used(10). For each of the parameters test characteristics were calculated for the standard threshold, 90% and 95% accuracy, 90% and 95% sensitivity, 90% and 95% specificity and the highest Youden index (J), being defined as the point in the AUC curve with the farthest distance to the diagonal line; calculated as highest value (J) =sensitivity+specificity−1. Discriminative performance for the new cutoffs of each of the parameters were calculated using the pROC package (31).

RESULTS

Characteristics of the Patient Cohort

Of 1 268 CoArtHA participants, 1 125 (49% from Tanzania, 51% from Lesotho) had evaluable ECG and echocardiography data (Figure 2). Median age was 53.4 (IQR:44.6-64.4) years, 28% were male, and 38% were HIV positive. LVH by echocardiography was identified in 56 participants (5%). Participants with LVH were older, more often female, more often with a history of hypertension and had higher systolic and diastolic blood pressure, and body mass index compared with those without LVH (Table 2).

Table 2: Baseline demographic and clinical characteristics of the study sample, overall and regarding subgroups with echocardiographic signs for LVH

Variables	Overall (n=1125)	fTTE- LVH present (n=56)	fTTE- LVH absent (n=1069)	p-value
Tanzania, n (%)	553 (49.2)	47 (83.9)	506 (47.3)	< 0.001

Lesotho, n (%)	572 (50.8)	9 (16.1)	563 (52.7)	<0.001
Age, years, median (IQR)	53.4 (44.6 – 64.4)	59.0 (49.1 – 68.1)	53.2 (44.3 – 64.3)	0.009
Male, n (%)	314 (27.9)	8 (14.3)	306 (28.6)	0.029
HIV-positive, n (%)	423 (37.6)	10 (17.9)	413 (38.6)	0.003
Previously diagnosed HT, n (%)	469 (41.7)	34 (60.7)	435 (40.7)	0.012
Diabetes, n (%)	22 (2.0)	0	22 (2.1)	0.323
Diabetes never checked, n (%)	102 (9.1)	3 (5.4)	99 (9.3)	
BMI, (kg/m^2), median (IQR)	26.4 (22.8 – 30.7)	25.1 (21.5 – 28.1)	26.5 (22.8 – 30.7)	0.032
BSA, (m^2), median (IQR)	1.71 (1.55 – 1.85)	1.57 (1.47 – 1.76)	1.70 (1.56 – 1.85)	0.001
Systolic BP (mmHg), median (IQR)	149 (141 – 163)	165 (152 – 182)	148 (140 – 161)	<0.001
Diastolic BP (mmHg), median (IQR)	99 (93 – 106)	104 (98 – 116)	98 (93 – 105)	<0.001

fTTE - focused echocardiography, HT – hypertension, LVH-left ventricular hypertrophy, BMI - body mass index, BP- blood pressure, BSA- body surface area

Prevalence of LVH ECG markers

The overall prevalence of positive ECG markers according to the presence of echocardiographic signs for LVH is shown in Table 3. The highest prevalence of positive ECG LVH markers was observed with the general MESA ECG-LVH criterion (633/1125 [56.3%]) participants), the ethnicity- and gender-specific MESA ECG-LVH criterion (566/1125 [50.3%]) participants) and Sokolow-Lyon voltage index (390/1125 [34.7%]) participants. There were no significant differences in the prevalence of positive values of these criteria, as well as for the Framingham-adjusted Cornell voltage index, and Minnesota Code 3.3, between the group of patients fTTE - LVH and the patients without fTTE-LVH (p>0.05).

Table 3. *Prevalence of positive ECG markers in the entire cohort, as well as separated for the group with echocardiographic signs of LVH and those without.*

Index	Overall (n=1125)	Echocardio-graphic signs for LVH (n=56)	No echo-cardiographic signs for LVH (n=1070)	p-value
Cornell voltage criteria, > 2.0 mV (women), > 2.8 mV (men), n (%)	256 (22.8)	28 (50.0)	228 (21.3)	< 0.001
Cornell voltage product ≥ 243.6 mVms, n (%)	103 (9.2)	21 (37.5)	82 (7.7)	< 0.001
Cornell voltage product ≥ 244 mVms, n (%)	100 (8.9)	21 (37.5)	79 (7.4)	< 0.001
Cornell voltage product ≥ 243.6 mVms, n (%), adjusted	203 (18.0)	30 (53.6)	173 (16.2)	< 0.001

0.6mV (women)				
Cornell voltage product ≥ 244 mVms, n (%), adjusted 0.6 mV (women)	197 (17.5)	30 (53.6)	167 (15.6)	< 0.001
Cornell voltage product ≥ 243.6 mVms, n (%), adjusted 0.8 mV (women)	255 (22.7)	36 (64.3)	219 (20.5)	< 0.001
Cornell voltage product ≥ 244 mVms, n (%), adjusted 0.8 mV (women)	249 (22.1)	34 (60.7)	215 (20.1)	< 0.001
Novacode 6.1 LVH, ≥ 2.2 mV (women), ≥ 2.6 mv (men), n (%)	240 (21.3)	30 (53.6)	210 (19.6)	< 0.001
RaVL ≥ 1.1 mV, n (%)	190 (16.9)	23 (41.1)	167 (15.6)	< 0.001
general MESA ECG-LVH, ≥ 4.2 mV, n (%)	633 (56.3)	33 (58.9)	600 (56.1)	0.784
Ethnicity- and gender-specific MESA ECG-LVH criterion (African American), ≥ 4.3 mV (women), ≥ 4.8 mV (men), n (%)	566 (50.3)	30 (53.6)	536 (50.1)	0.716
Sokolow-Lyon voltage > 3.5 mV, n (%)	390 (34.7)	29 (51.8)	361 (33.8)	0.009
Sokolow-Lyon voltage product, ≥ 371 mVms, n (%)	172 (15.3)	24 (42.9)	148 (13.8)	< 0.001

Framingham-adjusted Cornell voltage, ≥ 2.0 mV (women), ≥ 2.8 mV (men), n (%)	564 (50.1)	34 (60.7)	530 (49.6)	0.179
Minnesota Code 3.1 (LVH without ST-T), n (%)	270 (24.0)	30 (53.6)	240 (22.5)	< 0.001
Minnesota Code 3.3, n (%)	205 (18.2)	4 (7.1)	201 (18.8)	0.419
Strain pattern, n (%)	44 (3.9)	12 (21.4)	32 (3.0)	< 0.001

ECG- electrocardiography, LVH- left ventricular hypertrophy, MESA- the Multi-Ethnic Study of Atherosclerosis

Characteristics of ECG parameters

Median values of the continuous ECG criteria in the group of participants with fTTE-LVH were significantly higher than in the group without fTTE-LVH, except for the General and male specific MESA ECG-LVH criterion and the male and female specific Framingham-adjusted Cornell voltage (Table S2).

Correlations between LVMI and ECG-LVH criteria

Continuous LVH ECG criteria were compared with continuous LVMI to determine the degree of correlation between these methods and to evaluate the extent to which ECG parameters can serve as markers for echocardiographic changes (Figure S1). Significant, weak to moderate, positive correlations were found between continuous LVMI and all ECG indices, with the highest correlations observed for unadjusted Cornell voltage product, Cornell voltage criteria, 0.6mV adjusted Cornell voltage product and R amplitude aVL (rho = 0.373, rho = 0.327, rho = 0.324 and rho = 0.304, respectively; $p < 0.001$ for all). The MESA ECG-LVH criteria

showed a significant positive but very weak correlation with LVMI (rho = 0.179, p < 0.001).

Diagnostic performance of ECG-LVH criteria

Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and the AUC for LVH were calculated for each ECG criterion with recommended standard cut-off values in comparison to echocardiographic signs of LVH (Table 4).

Using standard cut-offs, the Cornell voltage product (adjusted + 0.8 mV for women) achieved the highest AUC (0.719) with sensitivity 64% and specificity 80%, followed by the 0.6 mV-adjusted (AUC 0.690) and unadjusted (AUC 0.651) versions. Strain pattern and unadjusted Cornell voltage product yielded the highest specificity (> 90%) but lower sensitivity. MESA-derived criteria showed poor discrimination (AUC 0.517).

Table 4: Performance of standard ECG LVH criteria in overall study population.

Criteria	Overall (n=1125)					
	AUC	Specificity	Sensitivity	NPV	PPV	accuracy
Cornell voltage criteria, > 2.0 mV (women), > 2.8 mV (men)	0.643	0.787	0.500	0.968	0.109	0.772
Cornell voltage product, ≥ 243.6 mVms, unadjusted	0.649	0.923	0.375	0.966	0.204	0.896
Cornell voltage product, ≥ 244 mVms, unadjusted	0.651	0.926	0.375	0.966	0.210	0.899
Cornell voltage product, ≥	0.687	0.838	0.535	0.972	0.148	0.823

243.6 mVms, adjusted 0.6 mV						
Cornell voltage product, ≥ 244 mVms, adjusted 0.6 mV	0.690	0.844	0.536	0.972	0.152	0.828
Cornell voltage product, ≥ 243.6 mVms, adjusted 0.8 mV	0.719	0.795	0.643	0.977	0.141	0.788
Cornell voltage product, ≥ 244 mVms, adjusted 0.8 mV	0.703	0.799	0.607	0.975	0.137	0.789
Novacode 6.1 LVH, ≥ 2.2 mV (women), ≥ 2.6 mv (men)	0.670	0.804	0.536	0.971	0.125	0.790
R amplitude aVL ≥ 1.1 mV	0.627	0.844	0.411	0.965	0.121	0.822
general MESA ECG-LVH, ≥ 4.2 mV	0.514	0.439	0.589	0.953	0.052	0.446
Ethnicity- and gender-MESA ECG-LVH criterion (African American), ≥ 4.3 mV (women), ≥ 4.8 mV (men)	0.517	0.499	0.536	0.953	0.053	0.500
Sokolow-Lyon voltage > 3.5 mV	0.590	0.662	0.518	0.963	0.074	0.655
Sokolow-Lyon voltage product, ≥ 371 mVms	0.645	0.862	0.429	0.966	0.140	0.840
Framingham-adjusted	0.556	0.504	0.607	0.960	0.060	0.509

Cornell voltage, ≥ 2.0 mV (women), ≥ 2.8 mV (men)						
Minnesota Code 3.1 (LVH without ST-T)	0.656	0.775	0.536	0.970	0.111	0.764
Minnesota Code 3.3	0.456	0.758	0.154	0.966	0.020	0.739
Strain pattern	0.592	0.970	0.214	0.959	0.272	0.932

AUC: area under the curve; tn: true negative count, tp: true positive count, fn: false negative, fp: false positive. Specificity: tn / (tn + fp); Sensitivity: tp / (tp + fn); negative predictive value (NPV): tn / (tn + fn); positive predictive value (PPV): tp / (tp + fp) ; accuracy: (tp + tn) / N. Colours indicate first, second, third highest (dark green, green, light green) and lowest (orange) values per column.

Analysis of continuous ECG parameters to identify most promising ECG parameter as an indicator for LVH Detection

The ROC plot in Figure 3 provides a comparative analysis of the diagnostic performance of the studied ECG criteria as continuous values with regard to the presence of LVH to see if an improvement of the cut-off values would be possible. Among the indexes investigated, compared to the 'neutral' AUC value of 0.5, the Cornell voltage product adjusted with 0.8mV and 0.6mV (women), the unadjusted Cornell voltage product, and the R wave amplitude in aVL had the highest AUC values (0.765, 0.761, 0.738, and 0.708, respectively) with an acceptable discriminative property (32). The MESA ECG-LVH index showed the lowest AUC of the tested parameters (0.577).

Alternative cut off values for selected ECG parameters

Based on the previous results, we selected the three best criteria for further evaluation: Cornell voltage criteria, Cornell voltage product, and R amplitude aVL, as well as the MESA ECG-LVH index. We analysed both standard and optimized thresholds for these ECG LVH criteria to identify the most clinically applicable thresholds (Table S3, Figure S2). Considering the limited number of men diagnosed with fTTE- LVH in our cohort, we evaluated novel thresholds for the Cornell voltage criteria without sex-specific adjustments. Figure S2 illustrates the discriminative performance of each parameter using both traditional cut-off values and thresholds optimized for maximal Youden's index. It also reports the AUCs corresponding to cut-offs that achieve sensitivity, specificity, or accuracy greater than 90% and 95%, respectively (Table S3). Highest AUC (0.719) was calculated for the traditional cut-off of the Cornell voltage product adjusted with 0.8 mV (women). Figure 4 summarizes the best test and cut-off values for highest Youden index/AUC, sensitivity >90% and specificity >90% for the Cornell voltage product adjusted with 0.8 mV (women), despite AUC for sensitivity >90% was numerically higher for the unadjusted Cornell voltage product (0.599 vs. 0.620).

DISCUSSION

This sub-analysis of the CoArtHA trial provides several important insights into the diagnostic utility of ECG criteria for left ventricular hypertrophy (LVH) among hypertensive Black African adults..

First, LVH ECG indices showed a weak to moderate correlation with echocardiographic LV mass index (LVMI), with the Cornell voltage product and its female-adjusted version performing best. . Second, appliying traditional cut-off values yielded highest discriminative properties for the Cornell voltage product with 0.8 mV adjustment for women at a cut-off of 243.6 mVms, followed by the cuf-off of 244 mVms. Third, the limited sensitivity of ECG in diagnosing LVH highlights the need for tests with higher sensitivity and acceptable specificity. Rodrigues et al e.g. proposed lowering sex-specific thresholds for the Cornell voltage criteria to improve sensitivity (34). The CoArtHa study also aimed to enhance ECG criteria for LVH in African populations, supporting ethnic-specific thresholds. The Youden index is commonly used to identify optimal cut-off values, minimizing both false positives and negatives (35). Within our cohort novel cut-off values only have better discriminative properties than standard cut-offs, when high sensitivities or specifities are aimed for. Interestingly, the highest AUC for the detection of LVH was reached at the best Youden Index with the Cornell voltage product with adjustment of 0.8 mV for women at the cut-off of 243.6 mVms, showing a sensitivity of 64.3% and specificity of 79.6%. ECG criteria for LVH were originally designed to reach a specificity as high as 90% to 95%, which in our cohort was achieved only by the unadjusted Cornell voltage product and Strain pattern at standard cut-offs, with the latter having a lower sensitivity of 21% compared to 37.5% (36). An adapted best threshold for > 90% specificity could be using the Cornell voltage product adjusted with 0.8 mV for women at >277 mVms with a sensitivity of 42.9%. Regarding Cornell voltage criteria best Youden index at 2.25 mV showed higher AUC values and improved sensitivity to 53.6%, while maintaining specificity at a level of 79.4%. Further studies are needed to confirm the clinical usefulness of these thresholds for diagnosing LVH in Black African hypertensive patients.

Collectively, these findings demonstrate that standard ECG criteria especially the Cornell voltage product with a 0.8 mV adjustment for women remain applicable but may require minor threshold adjustments when used in African populations with untreated hypertension.

Several aspects of the present study deserve to be mentioned.

The weak to moderate correlations between ECG-LVH indices and echocardiographic LV mass index observed in our study are consistent with prior reports from both African and non-African cohorts.(5, 6, 9, 34, 36-38)

Our findings of variable but overall low-to-moderate sensitivity (0.15–0.59) combined with higher specificity (0.44–0.97) are consistent with previous studies in African adults with hypertension, which have repeatedly reported that standard ECG criteria for LVH show limited sensitivity but good specificity (5, 9, 36, 39, 40). In a study conducted in Nigeria in 90 subjects evaluating four ECG criteria, Cornell criterion and Sokolow-Lyon criterion showed a lower accuracy than our results, but the defined cut off for LVH in TTE was >125/m^2 for both sexes which is higher than the recommended gender-specific cutoff values we used (9). In a subgroup of 120 African American participants of the LIFE study, Sokolow-Lyon overestimated and Cornell voltage criteria underestimated the presence of LVH relative to white participants compared to TTE, in terms of sensitivity and specificity – but not in terms of overall test performance in ROC curve analysis (41). In line with our results, Cornell voltage product had the highest numerical AUC value of 0.665 in the LIFE study (41). Interestingly and in contrast to a study by Jain et al, comparing ECG parameter to cardiac MRI in several ethnicities within the MESA study and deriving the MESA ECG-LVH criteria, the general MESA ECG-LVH and the ethnicity- and gender- specific MESA ECG-LVH criterion had a low specificity and sensitivity in our

cohort.(10) Within the MESA cohort and when applying ethnicity and gender specific cut-offs, specificity and sensitivity for the participants of African American descent was 90% and 37-39%, respectively with an ROC AUC of 0.64.In addition to the geographical differences of the trials namely United States versus sub saharan Africa, there were also differences between the cohorts with a 50% proportion of males and a higher prevalence of MRI-LVH of 11% in the MESA study. Additionally participants were older and had an higher BMI. Another reason for the discrepancy may be the differences between MRI and TTE, but again in the MESA study, the agreement for LVH between the imaging modalities ranged from 77-98% with a kappa coefficient from 0.1-0.76(42). To our knowledge, the MESA criteria had not been externally validated.

Generally, in the CoArtHa study three particular ECG criteria (Cornell voltage criteria, Cornell voltage product (especially with adjustment), and R amplitude aVL) had better discriminative properties and were more sensitive than other criteria. This aligns with other studies in different ethnic populations that demonstrated that the Cornell-based criteria had superior diagnostic performance compared to Sokolov-Lyon, and other criteria (34, 40, 43, 44).

Regarding the prognostic value, presence of LVH is an important marker for mortality, especially in African American patients, making screening of this condition even more relevant(41, 45, 46). This is true not only for LVH diagnosed by TTE or MRI but also for LVH detected by ECG criteria in different settings, even though the prevalence of LVH by ECG is higher than by imaging.

For example, within the LIFE study, regression of LVH defined by Cornell voltage criteria, Sokolov-Lyon voltage criteria or ECG Strain pattern was associated with an improved cardiovascular outcome independent of BP reduction (47). Additionally, presence of these markers at baseline or development of new Strain pattern over

time were predictors of cardiovascular events (47). Moreover, in a meta-analysis conducted by Zhigang You et al, Cornell voltage criteria had a stronger predictive value for cardiovascular risk than the Sokolov-Lyon index and Cornell voltage product in general populations, without studies coming from the African continent. (48).

Of note, there is evidence that the information from TTE and ECG may complement each other, with, however, a higher impact of the TTE diagnosis. A study by Seko and colleagues evaluated the prognostic relevance of presence and absence of LVH in TTE and ECG by using Cornell product in hospitalized asian participants. When considering the resulting four possible patterns of TTE/ECG, namely +/+, +/-, -/+ and -/-, the hazard ratio for major adverse cardiovascular events over 3 years was 1.63 (1.16-2.28), 1.68 (1.23-2.30) and 1.09 (0.85-1.41) compared to patients no evidence of LVH(49). Therefore, ECG remains a useful tool for risk stratification in hypertension not only in countries where poor technical provision and costs may limit the use of echocardiography. Therefore, it may be clinically feasible to use ECG with tailored cutoff values to identify a group of patients at lower risk for LVH and deprioritise them for further imaging.

Our study has several limitations. Firstly, in our cohort of treatment-naïve adults with hypertension, the prevalence of fTTE LVH was 5%, resulting in 56 participants with LVH only. The low number, together with the overrepresentation of female participants within the study as well as within those with an echocardiographically confirmed LVH, makes it difficult to generalize the results, especially to men, speaking for the need of a validation in other cohorts in Africa. Secondly, the prevalence of echocardiographic LVH in hypertension varies based on LVM indexation and cut-off values. Adebiyi et al. examined different echocardiographic thresholds in 457 hypertensive native Africans, finding LVH prevalence ranged from

30.9% to 56.0%(37, 50) . The highest was with LVM indexed to height$^{2.7}$ (49.2 g/ht$^{2.7}$ in men, 46.7 g/ht$^{2.7}$ in women), and the lowest with BSA indexation (125 g/m^2 for both sexes)(50) . This aligns with studies in southwestern Nigeria and the MAVI (MAssa Ventricolare sinistra nel soggetto Iperteso) study, which used a higher LVMI cut-off (>125 g/m^2) and reported LVH prevalence of 32.2% and 27.2%, respectively(6, 9). Our analysis applies the American Society of Echocardiography definition (>115 g/m^2 in men, >95 g/m^2 in women), widely used in clinical practice and linked to adverse cardiovascular outcomes(28).

Thirdly, the fTTE in our study were not performed by fully trained cardiologists, but by doctors and nurses after a short-time training, possibly resulting in differences when compared to board certified cardiologists or cardiac sonographer. However, analyses of echocardiographies were done in a central site with the support of an artificial intelligence algorithm and interpretation of cardiologists. This approach was used also in a population-based survey by our group and has been proven to be feasible(27, 51). Additionally there is evidence that TTE image quality has limited influence on the reliability and performance of LVM assessment, when compared to cMRI(42). Finally, we could not analyse a correlation of ECG parameter with outcomes such as morbidity or mortality.

In conclusion, in this population of treatment-naïve Black Africans with uncomplicated and untreated hypertension in rural Africa, the Cornell voltage product with adjustment of 0.8 mV for women had the best diagnostic properties when compared to alternative LVH ECG criteria, with a moderate association with left ventricular myocardial mass measured by focused echocardiography, indexed to body surface area and should be the preferred ECG parameter when full or point-of-care echocardiography is not available. We found, that application of standard cut-offs are

in line with best Youden Index. Specificity can be increased to 90% using a cut-off value of 277 mVms. Implementing ECG and using the best performing criteria in routine clinical care may contribute to improve the diagnosis of LVH at screening stage and may allow to identify a group of patients at lower or higher risk for hypertension-mediated cardiac damage to de-or prioritize for further echocardiography. However, given the rapid advancements in imaging technology, the increasing integration of artificial intelligence (AI) and a more comprehensive and dynamic assessment of cardiac function by fTTE, it is plausible that ECG may be gradually supplanted by fTTE in the coming years. Nonetheless, continued refinement of ECG-LVH criteria and AI-based diagnostic approaches may further enhance the utility of ECG as an accessible screening tool in resource-limited settings.

Acknowledgments

The authors thank all investigators, staff, and participants of the CoArtHA study for their valuable contributions.

Sources of Funding

This trial was funded by the Swiss National Science Foundation (grant 32003B185263/1). Additional funding for focused echocardiography analysis was granted by the Cardiovascular Research Foundation Basel

Disclosures: PD Annina Salome Vischer has received personal fees from Bristol Myers Squibb, Amarin, Servier, Medtronic, Vifor, NovoNordisk, AstraZeneca outside the submitted work. Dr Mapesi reported being employed by Roche outside the submitted work. Prof Rohacek reported receiving grants from Else Kröner Fresenius

Foundation outside the submitted work. Prof Labhardt reported receiving travel support from Gilead Sciences and ViiV outside the submitted work. PD Burkard reported receiving grants from Swiss National Science Foundation, Cardiovascular Research Foundation Basel, AstraZeneca, Daiichi Sankyo, Medtronic, Roche Diagnostics, Novartis, Novo Nordisk, Collabree, and Preventicus and lecture and/or travel fees paid to institution from Servier, Medtronic, Sanofi, Novartis, and Daiichi Sankyo outside the submitted work. Prof Weisser reported receiving grants from the Swiss National Science Foundation for implementation and conduct of the study and travel grants for conference attendance from MSD and Gilead. Dr. Oehri reported funds from Goldschmidt-Jacobsen Stiftung outside the submitted work. No other disclosures were reported.

References:

1. Havranek EP, Froshaug DB, Emserman CD, Hanratty R, Krantz MJ, Masoudi FA, et al. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med. 2008;121(10):870-5.
2. Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023.
3. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.

4. Chapman JN, Mayet J, Chang CL, Foale RA, Thom SA, Poulter NR. Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. Am J Hypertens. 1999;12(5):437-42.
5. Jingi AM, Noubiap JJ, Kamdem P, Kingue S. Determinants and improvement of electrocardiographic diagnosis of left ventricular hypertrophy in a black African population. PLoS One. 2014;9(5):e96783.
6. Verdecchia P, Dovellini EV, Gorini M, Gozzelino G, Lucci D, Milletich A, et al. Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrophy in hypertension: the MAVI study. Ital Heart J. 2000;1(3):207-15.
7. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37(2):161-86.
8. Romhilt DW, Estes EH, Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J. 1968;75(6):752-8.
9. Ogunlade O, Akintomide AO. Assessment of voltage criteria for left ventricular hypertrophy in adult hypertensives in south-western Nigeria. J Cardiovasc Dis Res. 2013;4(1):44-6.
10. Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010;159(4):652-8.
11. Mapesi H, Gupta R, Wilson HI, Lukau B, Amstutz A, Lyimo A, et al. The coArtHA trial-identifying the most effective treatment strategies to control arterial hypertension in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials. 2021;22(1):77.
12. Mapesi H, Rohacek M, Vanobberghen F, Gupta R, Wilson HI, Lukau B, et al. Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho: A Randomized Clinical Trial. JAMA Cardiol. 2025.
13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104.
14. Belghazi J, El Feghali RN, Moussalem T, Rejdych M, Asmar RG. Validation of four automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension. Vasc Health Risk Manag. 2007;3(4):389-400.
15. Alchaghouri S, Wong KY, Perry RA, Ramsdale DR, Somauroo JD, Pyatt JR. QT peak prolongation is not associated with left ventricular hypertrophy in teenage professional football players. Ann Noninvasive Electrocardiol. 2007;12(2):104-10.
16. Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M. New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Hypertension. 2004;44(2):175-9.
17. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20(5):1180-6.
18. Rautaharju PM, Park LP, Chaitman BR, Rautaharju F, Zhang Z-M. The novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. Journal of Electrocardiology. 1998;31(3):157-87.
19. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81(3):815-20.
20. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
21. Sparapani R, Dabbouseh NM, Gutterman D, Zhang J, Chen H, Bluemke DA, et al. Detection of Left Ventricular Hypertrophy Using Bayesian Additive Regression Trees: The MESA. J Am Heart Assoc. 2019;8(5):e009959.

22. Norman JE, Jr., Levy D, Campbell G, Bailey JJ. Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm. J Am Coll Cardiol. 1993;21(7):1680-6.
23. Prineas RJ, Crow RS, Zhang Z-M. The Minnesota Code Manual of Electrocardiographic Findings2010.
24. Inoue YY, Soliman EZ, Yoneyama K, Ambale-Venkatesh B, Wu CO, Sparapani R, et al. Electrocardiographic Strain Pattern Is Associated With Left Ventricular Concentric Remodeling, Scar, and Mortality Over 10 Years: The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2017;6(9).
25. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, et al. Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation. 2009;119(14):1883-91.
26. Tromp J, Bauer D, Claggett BL, Frost M, Iversen MB, Prasad N, et al. A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram. Nat Commun. 2022;13(1):6776.
27. Firima E, Gonzalez L, Manthabiseng M, Bane M, Lukau B, Leigh B, et al. Implementing focused echocardiography and AI-supported analysis in a population-based survey in Lesotho: implications for community-based cardiovascular disease care models. Hypertens Res. 2024;47(3):708-13.
28. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.
29. Kassambara A. ggpubr: 'ggplot2' Based Publication Ready Plots. R package version 0.6.0 ed2023.
30. Leclezio L, Jansen A, Whittemore VH, de Vries PJ. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol. 2015;52(1):16-24.
31. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
32. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315-6.
33. Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria2024.
34. Rodrigues SL, D'Angelo L, Pereira AC, Krieger JE, Mill JG. Revision of the Sokolow-Lyon-Rappaport and cornell voltage criteria for left ventricular hypertrophy. Arq Bras Cardiol. 2008;90(1):46-53.
35. Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2018;27(8):2374-83.
36. Jaggy C, Perret F, Bovet P, van Melle G, Zerkiebel N, Madeleine G, et al. Performance of classic electrocardiographic criteria for left ventricular hypertrophy in an African population. Hypertension. 2000;36(1):54-61.
37. Dada A, Adebiyi AA, Aje A, Oladapo OO, Falase AO. Standard electrocardiographic criteria for left ventricular hypertrophy in Nigerian hypertensives. Ethnic Dis. 2005;15(4):578-84.
38. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994;74(7):714-9.
39. Bombelli M, Vanoli J, Cuspidi C, Dell'Oro R, Facchetti R, Mancia G, et al. Comparison of electrocardiographic versus echocardiographic detection of left ventricular mass changes over time and evaluation of new onset left ventricular hypertrophy. J Clin Hypertens (Greenwich). 2023;25(4):343-9.
40. Abiodun OO, Anya T, Adekanmbi VT. Electrocardiographic Abnormalities in Nigerian Hypertensives With Echocardiographic Left Ventricular Hypertrophy. Cureus. 2024;16(5):e60170.
41. Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, et al. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2002;15(8):663-71.

42. Armstrong AC, Gjesdal O, Almeida A, Nacif M, Wu C, Bluemke DA, et al. Left ventricular mass and hypertrophy by echocardiography and cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Echocardiography. 2014;31(1):12-20.
43. Ricciardi D, Vetta G, Nenna A, Picarelli F, Creta A, Segreti A, et al. Current diagnostic ECG criteria for left ventricular hypertrophy: is it time to change paradigm in the analysis of data? J Cardiovasc Med (Hagerstown). 2020;21(2):128-33.
44. Park JK, Shin JH, Kim SH, Lim YH, Kim KS, Kim SG, et al. A comparison of cornell and sokolow-lyon electrocardiographic criteria for left ventricular hypertrophy in korean patients. Korean Circ J. 2012;42(9):606-13.
45. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561-6.
46. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345-52.
47. Bang CN, Devereux RB, Okin PM. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review. J Electrocardiol. 2014;47(5):630-5.
48. You Z, He T, Ding Y, Yang L, Jiang X, Huang L. Predictive value of electrocardiographic left ventricular hypertrophy in the general population: A meta-analysis. J Electrocardiol. 2020;62:14-9.
49. Seko Y, Kato T, Yamaji Y, Haruna Y, Nakane E, Haruna T, et al. Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes. Open Heart. 2021;8(2).
50. Adebiyi AA, Ogah OS, Aje A, Ojji DB, Adebayo AK, Oladapo OO, et al. Echocardiographic partition values and prevalence of left ventricular hypertrophy in hypertensive Nigerians. BMC Med Imaging. 2006;6:10.
51. Firima E, Gonzalez L, Khan MA, Manthabiseng M, Sematle MP, Bane M, et al. High Rates of Undiagnosed Target Organ Damage Among Adults with Elevated Blood Pressure or Diabetes Mellitus in a Community-Based Survey in Lesotho. J Epidemiol Glob Health. 2023;13(4):857-69.

Figures and figure legends:

Figure 1: Graphical abstract

Figure 2: Study flow chart and selection of participants. Legend: fTTE - focused echocardiography, ECG- electrocardiography

Figure 3. ROC plot with area under the curve (AUC) for continuous electrocardiography (ECG) parameters. Legend: ECG- electrocardiography, LVH- left ventricular hypertrophy, MESA- the Multi-Ethnic Study of Atherosclerosis

Figure 4. Discriminative performance of the Cornell voltage product adjusted with 0.8 mV (women) at the highest Youden index/AUC derived cut-offs and sensitivity >90% and specificity >90% cut-offs.

Supplementary Material.

Table S1. Interpretation Table of Spearman Rank-Order Correlation Coefficients (30)

Spearman ρ	**Correlation**
≥0.70	Very strong relationship

0.40-0.69	Strong relationship
0.30-0.39	Moderate relationship
0.20-0.29	Weak relationship
0.01-0.19	No or negligible relationship

Note: This descriptor applies to both positive and negative relationships.

Table S2: Median values (IQR) for different continuous ECG parameters overall and in participants with and without echocardiographic LVH

Index	Overall (n=1125)	Echocardiographic signs for LVH (n=56)	No echocardiographic signs for LVH (n=1070)	p
Cornell voltage criteria, mV	1.7 (1.3 – 2.2)	2.3 (1.7 – 2.8)	1.7 (1.3 – 2.1)	<0.001
Cornell voltage product, mVms, unadjusted	142. 8 (103.2 – 188.6)	199.2 (150.8 – 267.8)	140.4 (101.4 – 182.4)	<0.001
Cornell voltage product, mVms, adjusted 0.6 mV (women)	177.6 (140.4 – 223.6)	246.0 (201.6 – 320.4)	176.0 (139.4 – 220.8)	<0.001
Cornell voltage product, mVms, adjusted 0.8 mV (women)	192.4 (150.4 – 240.0)	206.2 (217.3 – 337.2)	189.2 (148.2 – 235.6)	<0.001

R amplitude aVL, mV	0.6 (0.3 – 0.9)	0.9 (0.6 – 1.4)	0.6 (0.3 – 0.9)	<0.001
general MESA ECG-LVH, mV	4.3 (3.5 – 5.4)	4.8 (3.7 – 6.4)	4.3 (3.4 – 5.3)	0.051
Sokolow-Lyon voltage, mV	3.1 (2.5 – 3.8)	3.6 (2.9 – 4.9)	3.1 (2.5 – 3.8)	0.003
Sokolow-Lyon voltage product, mVms	263.2 (207.2 – 328.0)	318.4 (250.3 – 429.4)	259.0 (205.2 – 327.6)	<0.001
Framingham-adjusted Cornell voltage, mVms	2.2 (1.2 – 3.3)	2.7 (1.7 – 3.8)	2.2 (1.2 – 3.2)	0.011

ECG- electrocardiography, LVH- left ventricular hypertrophy, MESA- the Multi-Ethnic Study of Atherosclerosis

Table S3: Diagnostic performance of selected ECG LVH criteria at different cut-off values.

Criteria	Threshold	AUC	Specificity	Sensitivity	NPV	PPV	accuracy

Cornell voltage criteria	> 2.0 mV (women), > 2.8 mV (men)	0.643	0.787	0.500	0.968	0.109	0.772
Youden	2.25	0.665	0.794	0.536	0.970	0.120	0.781
90 % Accuracy	2.85	0.592	0.930	0.286	0.961	0.176	0.898
95% Accuracy	infinite	0.500	0.999	0.036	0.952	0.667	0.951
90% Sensitivity	1.25	0.579	0.247	0.911	0.981	0.060	0.280
95% Sensitivity	1.05	0.564	0.163	0.964	0.989	0.057	0.203
90% Specificity	2.65	0.626	0.912	0.339	0.963	0.168	0.884
95% Specificity	2.95	0.581	0.949	0.214	0.958	0.179	0.912
Cornell voltage product, unadjusted	≥ 244 mVms	0.651	0.926	0.375	0.966	0.210	0.899
	≥ 243.6 mVms	0.649	0.923	0.375	0.966	0.204	0.896
Youden	183.2	0.689	0.752	0.625	0.975	0.117	0.746
90 % Accuracy	245.4	0.643	0.928	0.357	0.965	0.206	0.900
95%	426.5	0.508	0.999	0.018	0.951	0.500	0.950

Accuracy							
90% Sensitivity	117.3	0.620	0.348	0.893	0.984	0.067	0.375
95% Sensitivity	94.3	0.577	0.207	0.946	0.987	0.059	0.244
90% Specificity	231.2	0.656	0.901	0.411	0.967	0.178	0.876
95% Specificity	262.8	0.627	0.950	0.304	0.963	0.243	0.918
Cornell voltage product, adjusted 0.6 mV (women)	≥ 244 mVms	0.690	0.844	0.536	0.972	0.152	0.828
	≥ 243.6 mVms	0.687	0.838	0.535	0.972	0.148	0.823
Youden	222.6	0.666	0.766	0.661	0.977	0.129	0.761
90 % Accuracy	281.8	0.583	0.928	0.393	0.967	0.222	0.901
95% Accuracy	422.3	0.508	0.997	0.054	0.953	0.500	0.950
90% Sensitivity	143.4	0.644	0.285	0.893	0.981	0.061	0.316
95% Sensitivity	121.4	0.625	0.176	0.946	0.984	0.057	0.214
90%	263.6	0.627	0.900	0.411	0.967	0.178	0.876

Specificity							
95% Specificity	296.4	0.560	0.949	0.321	0.964	0.250	0.918
Cornell voltage product, adjusted 0.8 mV (women)	≥ 244 mVms	0.703	0.799	0.607	0.975	0.137	0.789
	≥ 243.6 mVms	0.719	0.795	0.643	0.977	0.142	0.788
Youden	243.6	0.650	0.796	0.643	0.977	0.142	0.788
90 % Accuracy	297.3	0.560	0.927	0.375	0.966	0.212	0.900
95% Accuracy	440.1	0.509	0.997	0.054	0.953	0.500	0.950
90% Sensitivity	156.4	0.665	0.304	0.893	0.982	0.063	0.333
95% Sensitivity	121.4	0.625	0.136	0.946	0.980	0.054	0.176
90% Specificity	277.8	0.589	0.900	0.429	0.968	0.183	0.876
95% Specificity	310.0	0.537	0.950	0.339	0.965	0.264	0.920
R amplitude aVL	≥ 1.1 mV	0.627	0.844	0.411	0.965	0.121	0.822

Youden	0.65	0.641	0.567	0.714	0.974	0.080	0.574
90 % Accuracy	1.25	0.629	0.920	0.339	0.964	0.181	0.891
95% Accuracy	1.95	0.525	0.997	0.054	0.953	0.500	0.950
90% Sensitivity	0.35	0.598	0.284	0.911	0.984	0.063	0.316
95% Sensitivity	0.25	0.579	0.194	0.964	0.990	0.059	0.232
90% Specificity	1.15	0.623	0.889	0.357	0.963	0.144	0.862
95% Specificity	1.35	0.614	0.942	0.286	0.962	0.205	0.909
general MESA ECG-LVH	≥ 4.2 mV	0.514	0.439	0.589	0.953	0.052	0.446
Youden	5.15	0.600	0.718	0.482	0.964	0.082	0.707
90 % Accuracy	6.85	0.567	0.938	0.196	0.957	0.143	0.901
95% Accuracy	9.65	0.508	0.999	0.018	0.951	0.500	0.950
90% Sensitivity	2.35	0.485	0.059	0.911	0.926	0.048	0.101
95% Sensitivity	1.25	0.486	0.007	0.964	0.800	0.048	0.055

90% Specificity	6.35	0.574	0.897	0.250	0.958	0.123	0.864
95% Specificity	7.05	0.563	0.948	0.179	0.957	0.152	0.909

AUC, area under the curve; NPV - negative predictive value, PPV - positive predictive value

Figure S1. Scatter plots showing correlation between continuous ECG parameters and LV mass index from TTE parameters.



Panel A: Cornell voltage criteria; Panel B: unadjusted Cornell voltage product; Panel C: Cornell voltage product, adjusted for women 0.6 mV; Panel D: Cornell voltage product, adjusted for women 0.8 mV; Panel E: R amplitude in lead aVL; Panel F: General MESA ECG-LVH; Panel G: Sokolow-Lyon voltage; Panel H: Sokolow-Lyon product; Panel I: Framingham-adjusted Cornell voltage

Figure S2: Comparison of AUCs for traditional vs. Youden-index-derived cut-offs, and AUCs at sensitivity, specificity, or accuracy levels exceeding 90% and 95%.


A
Overall
sensitivity
1-specificity
cutoff Cornell criteria
Traditional > 2.0 mV (f), > 2.8 mV (m)
Youden > 2.5 mV
Sensitivity 90% > 1.25 mV
Sensitivity 95% > 1.05 mV
Specificity 90% > 2.65 mV
Specificity 95% > 2.95 mV
Accuracy 90% > 2.85 mV
Accuracy 95% infinite
AUC: 0.643
AUC: 0.665
AUC: 0.579
AUC: 0.564
AUC: 0.626
AUC: 0.581
AUC: 0.592
AUC: 0.500
B
Overall
sensitivity
1-specificity
cutoff Cornell product unadjusted
Traditional ≥ 244 mVms
Traditional ≥ 243.6 mVms
Youden > 183.2 mVms
Sensitivity 90% > 117.3 mVms
Sensitivity 95% > 94.3 mVms
Specificity 90% > 231.2 mVms
Specificity 95% > 262.8 mVms
Accuracy 90% > 245.4 mVms
Accuracy 95% > 426.5 mVms
AUC: 0.651
AUC: 0.649
AUC: 0.689
AUC: 0.620
AUC: 0.577
AUC: 0.656
AUC: 0.627
AUC: 0.643
C
Overall
sensitivity
1-specificity
cutoff Cornell product adjusted 0.6mV
Traditional ≥ 244 mVms
Traditional ≥ 243.6 mVms
Youden > 222.6 mVms
Sensitivity 90% > 143.4 mVms
Sensitivity 95% > 121.4 mVms
Specificity 90% > 263.6 mVms
Specificity 95% > 296.4 mVms
Accuracy 90% > 281.8 mVms
Accuracy 95% > 422.3 mVms
AUC: 0.690
AUC: 0.687
AUC: 0.713
AUC: 0.589
AUC: 0.561
AUC: 0.658
AUC: 0.635
AUC: 0.660
D
Overall
sensitivity
1-specificity
cutoff Cornell product adjusted 0.8mV
Traditional ≥ 244 mVms
Traditional ≥ 243.6 mVms
Youden > 243.6 mVms
Sensitivity 90% > 156.4 mVms
Sensitivity 95% > 121.4 mVms
Specificity 90% > 277.8 mVms
Specificity 95% > 310.0 mVms
Accuracy 90% > 297.3 mVms
Accuracy 95% > 440.1 mVms
AUC: 0.703
AUC: 0.719
AUC: 0.719
AUC: 0.599
AUC: 0.541
AUC: 0.664
AUC: 0.645
AUC: 0.651
E
Overall
sensitivity
1-specificity
cutoff R amplitude aVL
Traditional ≥ 1.1 mV
Youden > 0.65 mV
Sensitivity 90% > 0.35 mV
Sensitivity 95% > 0.25 mV
Specificity 90% > 1.15 mV
Specificity 95% > 1.35 mV
Accuracy 90% > 1.25 mV
Accuracy 95% > 1.95 mV
AUC: 0.627
AUC: 0.641
AUC: 0.598
AUC: 0.579
AUC: 0.623
AUC: 0.614
AUC: 0.629
AUC: 0.525
F
Overall
sensitivity
1-specificity
cutoff MESA ECG LVH
Traditional ≥ 4.2 mV
Youden > 5.15 mV
Sensitivity 90% > 2.35 mV
Sensitivity 95% > 1.25 mV
Specificity 90% > 6.35 mV
Specificity 95% > 7.05 mV
Accuracy 90% > 6.85 mV
Accuracy 95% > 9.65 mV
AUC: 0.514
AUC: 0.600
AUC: 0.485
AUC: 0.486
AUC: 0.574
AUC: 0.563
AUC: 0.567
AUC: 0.508

Study population

- 1125 participants from Tanzania and Lesotho
- Untreated, uncomplicated hypertension

Methods

LVH by focussed TTE (LVMI to BSA) >95g/m² (women), >115 g/m² (men)



Standard ECG criteria

Key Results

Criterion	Specificity	Sensitivity	NPV	PPV	Accuracy
Sokolow Lyon voltage	0.662	0.518	0.963	0.074	0.655
R amplitude aVL	0.844	0.411	0.965	0.121	0.822
Gender-adjusted Cornell voltage (0.8 mV)	0.797	0.500	0.968	0.109	0.772
Cornell voltage product	0.923	0.375	0.966	0.204	0.896
General MESA ECG LVH	0.439	0.589	0.953	0.052	0.446
Ethnicity- and gender- MESA ECG -LVH	0.499	0.536	0.953	0.053	0.500

+ Gender adjusted Cornell voltage product AUC=0.765

Conclusion:

Cornel Voltage product adjusted by 0.8 mV (women):

- Best diagnostic perfomance for LV detection at 243.6 mVms (standard)
- A higher cut-off (277.8 mVms) increased specifity to > 90%
- May support risk stratification and efficient use of TTE in low-resource settings


Participants of CoArtHa Trial n = 1268
Lesotho n = 600
Tanzania n = 668
Tanzania:
missing/insufficient quality fTTE n = 100
missing ECG n = 14
missing/insufficient quality fTTE and ECG n = 1
Lesotho:
missing/insufficient quality fTTE n = 20
missing ECG n = 8
missing/insufficient quality fTTE and ECG n = 0
Participants with full data
Tanzania:
n = 553
Participants with full data
Lesotho:
n = 572


Overall
sensitivity
1-specificity
0.00
0.25
0.50
0.75
1.00
ECG parameter
a Cornell Voltage Criteria
a Cornell Product unadjusted
a Cornell Product adjusted 0.6mV
a Cornell Product adjusted 0.8mV
a R amplitude aVL
a MESA ECG LVH
a Sokolow Lyon Voltage
a Sokolow Lyon Product
a Framingham-adjusted Cornell
AUC: 0.704
AUC: 0.738
AUC: 0.761
AUC: 0.765
AUC: 0.708
AUC: 0.577
AUC: 0.617
AUC: 0.671
AUC: 0.600


1.00
0.75
0.50
0.25
0.00
sensitivity
0.00
0.25
0.50
0.75
1.00
1-specificity
best test and cutoff per focus
highest Youden/AUC
a
Cornell product adjusted 0.8 mV > 243.6mVms
AUC: 0.719
high Sensitivity
a
Cornell product adjusted 0.8 mV > 156.4mVms
AUC: 0.599
high Specificity
a
Cornell product adjusted 0.8 mV > 277.8mVms
AUC: 0.664